HERON THERAPEUTICS INC (HRTX) Stock Price, Quote, News and Overview
NASDAQ:HRTX - Nasdaq - US4277461020 - Common Stock - Currency: USD
HRTX Quote, Performance and Key Statistics
NASDAQ:HRTX (5/30/2025, 2:35:03 PM)
1.89
-0.02 (-1.05%)
The current stock price of HRTX is 1.89 USD. In the past month the price decreased by -21.07%. In the past year, price decreased by -48.38%.
HRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.28B | ||
| AMGN | AMGEN INC | 13.84 | 154.50B | ||
| GILD | GILEAD SCIENCES INC | 14.25 | 137.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.59B | ||
| ARGX | ARGENX SE - ADR | 98.14 | 35.18B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.28 | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.08B | ||
| NTRA | NATERA INC | N/A | 21.31B | ||
| BIIB | BIOGEN INC | 8.29 | 19.23B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.64 | 14.29B |
Related stock screener links
About HRTX
Company Profile
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 122 full-time employees. The company creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Company Info
HERON THERAPEUTICS INC
100 Regency Forest Drive, Suite 300
Cary NORTH CAROLINA 92121 US
CEO: Barry Quart
Employees: 122
Phone: 18582514400
HERON THERAPEUTICS INC / HRTX FAQ
What is the stock price of HERON THERAPEUTICS INC today?
The current stock price of HRTX is 1.89 USD. The price decreased by -1.05% in the last trading session.
What is the ticker symbol for HERON THERAPEUTICS INC stock?
The exchange symbol of HERON THERAPEUTICS INC is HRTX and it is listed on the Nasdaq exchange.
On which exchange is HRTX stock listed?
HRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HERON THERAPEUTICS INC stock?
9 analysts have analysed HRTX and the average price target is 5.1 USD. This implies a price increase of 169.84% is expected in the next year compared to the current price of 1.89. Check the HERON THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HERON THERAPEUTICS INC worth?
HERON THERAPEUTICS INC (HRTX) has a market capitalization of 288.34M USD. This makes HRTX a Micro Cap stock.
How many employees does HERON THERAPEUTICS INC have?
HERON THERAPEUTICS INC (HRTX) currently has 122 employees.
What are the support and resistance levels for HERON THERAPEUTICS INC (HRTX) stock?
HERON THERAPEUTICS INC (HRTX) has a support level at 1.85 and a resistance level at 1.92. Check the full technical report for a detailed analysis of HRTX support and resistance levels.
Is HERON THERAPEUTICS INC (HRTX) expected to grow?
The Revenue of HERON THERAPEUTICS INC (HRTX) is expected to grow by 13.07% in the next year. Check the estimates tab for more information on the HRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HERON THERAPEUTICS INC (HRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HRTX, evaluating the profitability, health, valuation and growth aspects
- HERON THERAPEUTICS INC (HRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HERON THERAPEUTICS INC (HRTX) Sales and EPS estimates to see what analysts future expectations are.
- HERON THERAPEUTICS INC (HRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HERON THERAPEUTICS INC (HRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- HERON THERAPEUTICS INC (HRTX) Stock Chart to make your own analysis
- HERON THERAPEUTICS INC (HRTX) Latest news and press-releases to stay up to date.
Does HERON THERAPEUTICS INC (HRTX) stock pay dividends?
HRTX does not pay a dividend.
When does HERON THERAPEUTICS INC (HRTX) report earnings?
HERON THERAPEUTICS INC (HRTX) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of HERON THERAPEUTICS INC (HRTX)?
HERON THERAPEUTICS INC (HRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.06).
What is the Short Interest ratio of HERON THERAPEUTICS INC (HRTX) stock?
The outstanding short interest for HERON THERAPEUTICS INC (HRTX) is 22.04% of its float. Check the ownership tab for more information on the HRTX short interest.
HRTX Technical Analysis
HRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HRTX. HRTX may be in some trouble as it scores bad on both profitability and health.
HRTX Financial Highlights
Over the last trailing twelve months HRTX reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 90.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to HRTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 69.77% and a revenue growth 13.07% for HRTX